Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis
European Radiology · 2024
DOI: 10.1007/s00330-024-10634-6 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Radiology, 2024. Verfasst von Gun Ha Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Son…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Propensity Score. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To compare the efficacy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for patients with single small (≤ 3 cm) hepatocellular carcinoma (HCC) and preserved liver function (Child-Pugh class A). MATERIALS AND METHODS: The clinical features of treatment-naïve patients who underwent TACE and RFA as first-line treatment were balanced through propensity score matching (PSM). The primary endpoint was overall survival (OS), and the secondary endpoints were local tumor recurrence (LTR) and recurrence-free survival (RFS). RESULTS: The analysis included 440 patients who received TACE, and 430 patients who received RFA. After PSM adjustment (323 pairs), the 5- and 10-year OS rates were 81% and 61%, respectively, in patients who underwent RFA, and 77% and 51%, respectively, for patients who underwent TACE (p = 0.021). Subgroup analyses showed that OS, LTR, and RFS were homogeneously better in the RFA group. CONCLUSION: RFA was associated with better survival outcomes than TACE in patients with single small HCC and preserved liver function. CLINICAL RELEVANCE STATEMENT: This large-scale comparative study provides evidence that radiofrequency ablation has a better overall survival rate than chemoembolization for small (≤ 3 cm) hepatocellular carcinomas. KEY POINTS: • The relative effectiveness of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for early HCC is unclear. • Overall survival rate was significantly higher in the RFA group. • The effects of RFA on overall survival, local tumor recurrence, and recurrence-free survival were homogeneously better in all subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea.
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. jhkimrad@amc.seoul.kr.
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Zitieren
APA
Kim, G. H., Kim, J. H., Shim, J. H., Kim, S. Y., Kim, P. H., Ko, H. K., Gwon, D. I., Shin, J. H., Lee, S. J., Chu, H. H., Won, H. J., Shin, Y. M., & Kim, N. (2024). Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis. European Radiology. https://doi.org/10.1007/s00330-024-10634-6
Vancouver
Kim GH, Kim JH, Shim JH, Kim SY, Kim PH, Ko HK, et al. Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis. European Radiology. 2024. doi:10.1007/s00330-024-10634-6
BibTeX
@article{Kim2024,
author = {Kim, Gun Ha and Kim, Jin Hyoung and Shim, Ju Hyun and Kim, So Yeon and Kim, Pyeong Hwa and Ko, Heung-Kyu and Gwon, Dong Il and Shin, Ji Hoon and Lee, So Jung and Chu, Hee Ho and Won, Hyung Jin and Shin, Yong Moon and Kim, Nayoung},
title = {Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis},
journal = {European Radiology},
year = {2024},
doi = {10.1007/s00330-024-10634-6}
}
EUVIMED